Synapse - Robert Motzer

Results (1243)

KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Albiges, L.; Suárez, C.; Powles, T.; Motzer, R. J.; Stadler, W. M.; Miller, W. H. Jr; Rojas, C.; Peer, A.; Goh, J. C.; Park, S. H.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313

Meeting Abstract

Albiges, L.; Motzer, R. J.; Trevino, S.; Kanesvaran, R.; Centkowski, P.; Reimers, M. A.; Sade, J. P.; Pouessel, D.; Biscaldi, E.; Esteban, E.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)

Meeting Abstract

McGregor, B. A.; Choueiri, T. K.; Albiges, L.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P. C.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study

Meeting Abstract

Beckermann, K.; Choueiri, T. K.; Motzer, R. J.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P. C.; McKay, R. R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies

Meeting Abstract

Shah, N. J.; Ravilla, R.; Osterland, A. J.; Todoroff, K.; Wang, C. Y.; Rane, P.; Saal, H.; Wang, D.; Motzer, R. J.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214

Meeting Abstract

Xu, W.; Vemula, S. V.; Motzer, R. J.; Chhibber, A.; Chowbene, D.; Perrot, N.; Liu, X.; Bonventre, J.; Choueiri, T. K.; McDermott, D. F.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: Final analysis of the phase III JAVELIN Renal 101 trial

Journal Article

Choueiri, T. K.; Penkov, K.; Uemura, H.; Campbell, M. T.; Pal, S.; Kollmannsberger, C.; Lee, J. L.; Venugopal, B.; van den Eertwegh, A. J. M.; Negrier, S.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Biomarker analyses from the phase III randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

Journal Article

Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Neoadjuvant and adjuvant immune-based approach for renal cell carcinoma: Pros, cons, and future directions

Review

Marandino, L.; Campi, R.; Amparore, D.; Tippu, Z.; Albiges, L.; Capitanio, U.; Giles, R. H.; Gillessen, S.; Kutikov, A.; Larkin, J.; more...
European Urology Oncology (2025)

Fulltext@MSK | Save

Clinical outcomes and targeted genomic analysis of renal cell carcinoma brain metastases treated with stereotactic radiosurgery

Journal Article

Ma, J.; del Balzo, L.; Walch, H.; Khaleel, S.; Knezevic, A.; Flynn, J.; Zhang, Z.; Eichholz, J.; Doshi, S. D.; Voss, M. H.; more...
European Urology Oncology (2025)

Fulltext@MSK | Save